Supplementary material: Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome

<p dir="ltr"><b>This is a peer-reviewed graphical abstract for the article</b><b> </b><b>'</b><b>A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research.</i></b></p><ul><li><b>Additional statistical methods</b></li><li><b>Supplementary Table 1:</b><b> </b>PRUCISION vs ItchRO instruments.</li><li><b>Supplementary Table 2</b><b>:</b><b> </b>ICONIC patient disposition.</li><li><b>Supplementary Table 3</b><b>:</b><b> </b>ASSERT/ASSERT-EXT patient disposition.</li><li><b>Supplementary Table 4</b><b>:</b><b> </b>Baseline characteristics for pruritus and safety analyses at Week 48 (ASSERT full analysis set)</li><li><b>Supplementary Table 5</b><b>:</b> Baseline characteristics for sBA analyses at Week 48 (ASSERT full analysis set)</li><li><b>Supplementary Table 6</b><b>:</b> Baseline Characteristics for HRQoL analyses at Week 48 (ASSERT full analysis set)</li></ul><p dir="ltr"><b>Aim: </b>Alagille syndrome (ALGS) is a rare genetic disorder associated with cholestasis and subsequent severe pruritus, which significantly impacts patient quality of life (QoL).

Odevixibat (ODX) and maralixibat (MRX) are ileal bile acid transporter inhibitors approved for the treatment of cholestatic pruritus in ALGS. In the absence of head-to-head data, this study aimed to compare the efficacy, safety, and health-related QoL (HRQoL) associated with ODX and MRX. <b>Materials & methods:</b> A population-adjusted unanchored indirect treatment comparison was conducted using patient-level data from the Phase III ASSERT/ASSERT-EXT studies (ODX) and published data from the Phase IIb ICONIC study (MRX).